BR112012025879A2 - compostos de triazol como inibidores de ksp - Google Patents
compostos de triazol como inibidores de kspInfo
- Publication number
- BR112012025879A2 BR112012025879A2 BR112012025879A BR112012025879A BR112012025879A2 BR 112012025879 A2 BR112012025879 A2 BR 112012025879A2 BR 112012025879 A BR112012025879 A BR 112012025879A BR 112012025879 A BR112012025879 A BR 112012025879A BR 112012025879 A2 BR112012025879 A2 BR 112012025879A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazole compounds
- compound
- formula
- ksp inhibitors
- ksp
- Prior art date
Links
- -1 triazole compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32465110P | 2010-04-15 | 2010-04-15 | |
| PCT/EP2011/055840 WO2011128381A1 (en) | 2010-04-15 | 2011-04-13 | Triazole compounds as ksp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012025879A2 true BR112012025879A2 (pt) | 2017-11-21 |
Family
ID=44009916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012025879A BR112012025879A2 (pt) | 2010-04-15 | 2011-04-13 | compostos de triazol como inibidores de ksp |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8546434B2 (https=) |
| EP (1) | EP2558450A1 (https=) |
| JP (1) | JP2013523867A (https=) |
| KR (1) | KR20130100056A (https=) |
| CN (1) | CN102844307A (https=) |
| AR (1) | AR080893A1 (https=) |
| AU (1) | AU2011239977B2 (https=) |
| BR (1) | BR112012025879A2 (https=) |
| CA (1) | CA2794406A1 (https=) |
| EA (1) | EA201201404A1 (https=) |
| MX (1) | MX2012011910A (https=) |
| TW (1) | TW201136925A (https=) |
| UY (1) | UY33332A (https=) |
| WO (1) | WO2011128381A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2558452A2 (en) * | 2010-04-15 | 2013-02-20 | Novartis AG | Oxazole and thiazole compounds as ksp inhibitors |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| CN118324664B (zh) * | 2024-03-14 | 2026-04-07 | 四川鸿日医药科技有限公司 | 一种丝氨酸衍生物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| PL375889A1 (en) | 2002-10-11 | 2005-12-12 | Cytokinetics, Inc. | Compounds for treating cellular proliferative diseases, compositions containing them and their application |
| RS50670B (sr) * | 2004-05-21 | 2010-06-30 | Novartis Vaccines And Diagnostics Inc. | Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori |
| KR101170925B1 (ko) * | 2004-06-18 | 2012-08-07 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물 |
| JP2008517057A (ja) * | 2004-10-19 | 2008-05-22 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | インドールおよびベンゾイミダゾール誘導体 |
| EP1856128A4 (en) * | 2005-01-19 | 2009-12-23 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| EP1868601A4 (en) * | 2005-04-07 | 2008-12-10 | Merck & Co Inc | MITOTIC KINESINE HEMMER |
| TW200800951A (en) | 2005-08-09 | 2008-01-01 | Novartis Ag | Substituted imidazole compounds as KSP inhibitors |
| US7325386B2 (en) | 2005-10-17 | 2008-02-05 | Etienne Kissling | Double action vertical form-fill-seal apparatus |
| AU2007323998B2 (en) | 2006-11-13 | 2011-09-22 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
| AU2008205169B2 (en) | 2007-01-05 | 2012-02-02 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5) |
| EP2558452A2 (en) | 2010-04-15 | 2013-02-20 | Novartis AG | Oxazole and thiazole compounds as ksp inhibitors |
-
2011
- 2011-04-13 JP JP2013504265A patent/JP2013523867A/ja active Pending
- 2011-04-13 EA EA201201404A patent/EA201201404A1/ru unknown
- 2011-04-13 US US13/085,746 patent/US8546434B2/en not_active Expired - Fee Related
- 2011-04-13 EP EP11715682A patent/EP2558450A1/en active Pending
- 2011-04-13 AU AU2011239977A patent/AU2011239977B2/en not_active Expired - Fee Related
- 2011-04-13 CN CN2011800184156A patent/CN102844307A/zh active Pending
- 2011-04-13 WO PCT/EP2011/055840 patent/WO2011128381A1/en not_active Ceased
- 2011-04-13 BR BR112012025879A patent/BR112012025879A2/pt not_active IP Right Cessation
- 2011-04-13 MX MX2012011910A patent/MX2012011910A/es not_active Application Discontinuation
- 2011-04-13 KR KR1020127029781A patent/KR20130100056A/ko not_active Withdrawn
- 2011-04-13 CA CA2794406A patent/CA2794406A1/en not_active Abandoned
- 2011-04-13 AR ARP110101254A patent/AR080893A1/es unknown
- 2011-04-14 UY UY0001033332A patent/UY33332A/es not_active Application Discontinuation
- 2011-04-14 TW TW100113030A patent/TW201136925A/zh unknown
-
2013
- 2013-08-28 US US14/012,167 patent/US20140056880A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR080893A1 (es) | 2012-05-16 |
| US20110256128A1 (en) | 2011-10-20 |
| TW201136925A (en) | 2011-11-01 |
| UY33332A (es) | 2011-12-01 |
| AU2011239977A1 (en) | 2012-11-01 |
| US8546434B2 (en) | 2013-10-01 |
| CA2794406A1 (en) | 2011-10-20 |
| MX2012011910A (es) | 2012-11-29 |
| EP2558450A1 (en) | 2013-02-20 |
| EA201201404A1 (ru) | 2013-04-30 |
| AU2011239977B2 (en) | 2014-11-27 |
| KR20130100056A (ko) | 2013-09-09 |
| WO2011128381A1 (en) | 2011-10-20 |
| CN102844307A (zh) | 2012-12-26 |
| US20140056880A1 (en) | 2014-02-27 |
| JP2013523867A (ja) | 2013-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| MX338554B (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| BR112013006355A2 (pt) | profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX343931B (es) | Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| PH12017501294A1 (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| BR112013020159A2 (pt) | método para inibir células tumorais de hamartoma | |
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| BR112012025879A2 (pt) | compostos de triazol como inibidores de ksp | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| MX2011011687A (es) | Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer. | |
| BR112012006070A2 (pt) | composições e métodos para tratar distúrbios convulsivos. | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. | |
| CU20130004A7 (es) | Agentes terapéuticos 976 | |
| MX356278B (es) | Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| BR112016006582A2 (pt) | terapia combinada laquinimod para o tratamento da esclerose múltipla | |
| BR112012006073A2 (pt) | composições e métodos para tratar espasticidade. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |